To the Point

Shoddy Practices at Big Drug Makers

So-called "compounding pharmacies" regulated by the states have been taking heat since the recent outbreak of meningitis. Today's New York Times reports that one-third of the drug manufacturing industry overseen by the Food and Drug Administration is off line because of "quality issues."

By Warren Olney • May 12, 2014 • 1 min read

So-called "compounding pharmacies" regulated by the states have been taking heat since the recent outbreak of meningitis. Today's New York Times reports that one-third of the drug manufacturing industry overseen by the Food and Drug Administration is off line because of "quality issues." Katie Thomas covers the business of healthcare for the New York Times.

Warren Olney
former KCRW broadcaster
Evan George
Director of Content, News
Katie Cooper
Producer, 'One year Later'
Caitlin Shamberg
KCRW
Katie Thomas
New York Times reporter covering health care and the drug industry

News

National

Politics

To the Point

Shoddy Practices at Big Drug Makers

So-called "compounding pharmacies" regulated by the states have been taking heat since the recent outbreak of meningitis. Today's New York Times reports that one-third of the drug manufacturing industry overseen by the Food and Drug Administration is off line because of "quality issues."

Share

To the Point

Shoddy Practices at Big Drug Makers

So-called "compounding pharmacies" regulated by the states have been taking heat since the recent outbreak of meningitis. Today's New York Times reports that one-third of the drug manufacturing industry overseen by the Food and Drug Administration is off line because of "quality issues."

Share